Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis.

@article{Woods2012BendamustineVC,
  title={Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis.},
  author={Beth S Woods and Neil Stephen Hawkins and William Christopher Nigel Dunlop and Alison O'Toole and Steve Bramham-Jones},
  journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  year={2012},
  volume={15 5},
  pages={
          759-70
        }
}
OBJECTIVES To evaluate the cost-effectiveness of bendamustine compared with chlorambucil as first-line treatment for patients with chronic lymphocytic leukemia who would be considered unsuitable for treatment with fludarabine combination chemotherapy regimens. METHODS A semi-Markov approach was used to estimate time in each health state. The model was parameterized primarily by using data from a phase III randomized, open-label trial comparing bendamustine with chlorambucil. It captured the… CONTINUE READING
BETA

Similar Papers

Loading similar papers…